to-the-point
New Retina Radio
Episode 53

Phase 3 Trials in Wet AMD [Miniseries: The Art of Drug Choice: Wet AMD and the Latest Data]

In episode 2 of the NRR miniseries "The Art of Drug Choice: Wet AMD and the Latest Data," Dr. Khanani and roundtable participants Drs. Fuller, London, and Weng review the latest phase 3 efficacy data from the HAWK/HARRIER, ARCHWAY, and CEDAR/SEQUOIA studies. Also, Dr. Weng shares the case of a wet AMD patient whose response to therapy and toleration of treatment burden mandated a change in treatment. Could brolucizumab (Beovu, Novartis) be a solution?

11/19/2020 | 30:12



Watch Webcast
More Episodes: